227 related articles for article (PubMed ID: 32561967)
1. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
3. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
[No Abstract] [Full Text] [Related]
4. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
5. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
Zong L; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Jan; 69(1):33-42. PubMed ID: 31781843
[TBL] [Abstract][Full Text] [Related]
6. Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental Schistosoma japonicum infection.
Zhang Y; Wu Y; Liu H; Gong W; Hu Y; Shen Y; Cao J
Parasit Vectors; 2021 Sep; 14(1):497. PubMed ID: 34565440
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract][Full Text] [Related]
8. Potential Novel Ovarian Cancer Treatment Targeting Myeloid-Derived Suppressor Cells.
Abiko K; Hayashi T; Yamaguchi K; Mandai M; Konishi I
Cancer Invest; 2021 Apr; 39(4):310-314. PubMed ID: 33428503
[TBL] [Abstract][Full Text] [Related]
9. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
[TBL] [Abstract][Full Text] [Related]
10. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.
Prima V; Kaliberova LN; Kaliberov S; Curiel DT; Kusmartsev S
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1117-1122. PubMed ID: 28096371
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
12. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
14. Expression of checkpoint molecules on myeloid-derived suppressor cells.
Ballbach M; Dannert A; Singh A; Siegmund DM; Handgretinger R; Piali L; Rieber N; Hartl D
Immunol Lett; 2017 Dec; 192():1-6. PubMed ID: 28987474
[TBL] [Abstract][Full Text] [Related]
15. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
Kong X; Peng H; Liu P; Fu X; Wang N; Zhang D
Cancer Sci; 2023 Jun; 114(6):2265-2276. PubMed ID: 36751987
[TBL] [Abstract][Full Text] [Related]
16. Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus.
Park MJ; Baek JA; Choi JW; Jang SG; Kim DS; Park SH; Cho ML; Kwok SK
Front Immunol; 2021; 12():606024. PubMed ID: 33986739
[TBL] [Abstract][Full Text] [Related]
17. Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.
Fleming V; Hu X; Weller C; Weber R; Groth C; Riester Z; Hüser L; Sun Q; Nagibin V; Kirschning C; Bronte V; Utikal J; Altevogt P; Umansky V
Cancer Res; 2019 Sep; 79(18):4715-4728. PubMed ID: 31337655
[TBL] [Abstract][Full Text] [Related]
18. ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression.
Liu C; Qiang J; Deng Q; Xia J; Deng L; Zhou L; Wang D; He X; Liu Y; Zhao B; Lv J; Yu Z; Lei QY; Shao ZM; Zhang XY; Zhang L; Liu S
Cancer Res; 2021 Dec; 81(23):5919-5934. PubMed ID: 34580061
[TBL] [Abstract][Full Text] [Related]
19. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
Front Immunol; 2020; 11():1299. PubMed ID: 32719675
[No Abstract] [Full Text] [Related]
20. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
Høgdall E; Høgdall C; Vo T; Zhou W; Huang L; Marton M; Keefe SM; Busch-Sørensen M; Sørensen SM; Georgsen J; Mejlgaard E; Nedergaard L; Steiniche T
Int J Gynecol Cancer; 2020 Jul; 30(7):1034-1042. PubMed ID: 32527769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
